Two weeks after disappointing the Street with higher-than-expected adverse event (AE) rates in its phase II trial of XP23829 in moderate to severe chronic plaque-type psoriasis, Xenoport Inc. changed course in dramatic fashion. Bowing to analyst recommendations, the company halted internal development of XP23829 while seeking to outlicense the candidate and other development-stage assets to focus, instead, on maximizing the commercial value of Horizant (gabapentin enacarbil).